Unique and Selective Targeting of Cdk Activity in Aggressive Carcinomas

Unique and Selective Targeting of Cdk Activity in Aggressive Carcinomas

Unique and Selective Targeting of Cdk Activity in Aggressive Carcinomas


Dr. Lisa Porter

University of Windsor

|

Dr. John Trant

University of Windsor

 

Cancers - especially aggressive ones - block proteins that protect cells from mutating into tumours. One family of these proteins is called Cyclin-Dependent Kinase Inhibitors or CKIs. Researchers have developed synthetic CKIs, but they can be overridden by another protein called Spy1. Porter and Trant hope their research will lead to the development of drugs that block Spy1 proteins, allowing the synthetic CKIs to be an effective treatment for aggressive cancers.

Related Programs:
Nucleus Cores:

FUNDER:

Ontario Institute for Cancer Research (OICR)

FUNDING:

$100,000

GRANT DURATION:

2019-2020

 

 

 

 

Loading...